"This new review provides one of the most comprehensive analyses so far of how GLP1 drugs interact with the underlying mechanisms of Alzheimer's," says physiologist Simon Cork
That said, there are potent effects of the drugs that help people eat less
The goal is successful maintenance, not speed
How Tranont says it works According to Tranont, Activate works through two primary mechanisms
This typically improves as treatment continues and should be discussed with your healthcare professional if persistent
Additional risk factors commonly present in patients prescribed GLP-1 receptor agonists include: Reduced physical activity and prolonged immobility Hypertension and other cardiovascular comorbidities Dyslipidaemia contributing to atherosclerosis Advanced age , as thrombotic risk increases with ageing Other important VTE risk factors include: Previous VTE or family history of clotting disorders Thrombophilia (inherited or acquired clotting disorders) Active cancer or cancer treatment Oestrogen-containing medications (HRT, combined oral contraceptives) Pregnancy and postpartum period Recent surgery, trauma or hospitalisation Long-haul travel with prolonged immobility Smoking When patients taking GLP-1 receptor agonists experience thrombotic events, it is important to consider these pre-existing risk factors as they often contribute significantly to clotting risk in this population
